255 related articles for article (PubMed ID: 29624655)
21. Acute generalized exanthematous pustulosis associated with ipilimumab and nivolumab.
Page B; Borradori L; Beltraminelli H; Yawalkar N; Hunger RE
J Eur Acad Dermatol Venereol; 2018 Jul; 32(7):e256-e257. PubMed ID: 28430376
[No Abstract] [Full Text] [Related]
22. Treatment of a patient with HIV and metastatic melanoma with consequitive ipilimumab and nivolumab.
Tomsitz D; Hein R; Biedermann T; Kohlmeyer J
J Eur Acad Dermatol Venereol; 2018 Jan; 32(1):e26-e28. PubMed ID: 28662283
[No Abstract] [Full Text] [Related]
23. 79-year Old Man on Nivolumab with Itchy Erythematous Patches.
Copur MS; Corey S
Oncology (Williston Park); 2020 Feb; 34(2):53-54. PubMed ID: 32645195
[TBL] [Abstract][Full Text] [Related]
24. Isolated Adrenocorticotropic Hormone Deficiency in Melanoma Patients Treated with Nivolumab.
Kitano S; Tatsuno K; Ishibe J; Shimauchi T; Fujiyama T; Ito T; Ogawa N; Tokura Y
Acta Derm Venereol; 2018 Jul; 98(7):704-705. PubMed ID: 29405244
[No Abstract] [Full Text] [Related]
25. Rituximab in the treatment of pembrolizumab-induced myasthenia gravis.
Crusz SM; Radunovic A; Shepherd S; Shah S; Newey V; Phillips M; Lim L; Powles T; Szlosarek PW; Shamash J; Rashid S
Eur J Cancer; 2018 Oct; 102():49-51. PubMed ID: 30138772
[No Abstract] [Full Text] [Related]
26. Late presentation of generalised bullous pemphigoid-like reaction in a patient treated with pembrolizumab for metastatic melanoma.
Parakh S; Nguyen R; Opie JM; Andrews MC
Australas J Dermatol; 2017 Aug; 58(3):e109-e112. PubMed ID: 27170423
[TBL] [Abstract][Full Text] [Related]
27. Isolated adrenocorticotropic hormone deficiency possibly caused by nivolumab in a metastatic melanoma patient.
Fujimura T; Kambayashi Y; Furudate S; Kakizaki A; Hidaka T; Haga T; Hashimoto A; Morimoto R; Aiba S
J Dermatol; 2017 Mar; 44(3):e13-e14. PubMed ID: 27440178
[No Abstract] [Full Text] [Related]
28. Bullous pemphigoid and nivolumab: Dermatologic management to support and continue oncologic therapy.
Panariello L; Fattore D; Annunziata MC; Piantedosi F; Gilli M; Fabbrocini G
Eur J Cancer; 2018 Nov; 103():284-286. PubMed ID: 30268391
[No Abstract] [Full Text] [Related]
29. Nivolumab PD-1 inhibitor immunotherapy associated with vulvar, perineal and perianal lichen sclerosus.
Wernham AGH; Shah F; Velangi S
Clin Exp Dermatol; 2019 Mar; 44(2):e22-e23. PubMed ID: 30430637
[No Abstract] [Full Text] [Related]
30. Development of bullous pemphigoid following radiation therapy combined with nivolumab for renal cell carcinoma: A case report of abscopal toxicities.
Huynh LM; Bonebrake BT; DiMaio DJ; Baine MJ; Teply BA
Medicine (Baltimore); 2021 Dec; 100(49):e28199. PubMed ID: 34889301
[TBL] [Abstract][Full Text] [Related]
31. [Vitiligo under checkpoint inhibitors].
Amini-Adle M; Dalle S
Ann Dermatol Venereol; 2018 Oct; 145(10):633-635. PubMed ID: 29866472
[No Abstract] [Full Text] [Related]
32. Rapidly Evolving Extensive Fluorodeoxyglucose-Positive Soft-Tissue Activity During Nivolumab Therapy.
Mangana J; Buset CS; Dummer R
JAMA Oncol; 2019 May; 5(5):730-731. PubMed ID: 30676614
[No Abstract] [Full Text] [Related]
33. Type 1 diabetes in a melanoma patient treated with ipilimumab after nivolumab.
Omodaka T; Kiniwa Y; Sato Y; Suwa M; Sato M; Yamaguchi T; Sato A; Miyake T; Okuyama R
J Dermatol; 2018 Oct; 45(10):e289-e290. PubMed ID: 29667767
[No Abstract] [Full Text] [Related]
34. Subcutaneous Fat Necrosis During Nivolumab Therapy for Metastatic Melanoma.
Pach J; Olamiju B; Weiss S; Damsky W; Leventhal J
JAMA Dermatol; 2021 Apr; 157(4):468-469. PubMed ID: 33688919
[No Abstract] [Full Text] [Related]
35. Dupilumab for the treatment of nivolumab-induced bullous pemphigoid: a case report and review of the literature.
Klepper EM; Robinson HN
Dermatol Online J; 2021 Sep; 27(9):. PubMed ID: 34755978
[TBL] [Abstract][Full Text] [Related]
36. Hypopituitarism and hypothyroidism following atrioventricular block during nivolumab treatment.
Oda T; Sawada Y; Okada E; Yamaguchi T; Ohmori S; Haruyama S; Yoshioka M; Nakamura M
J Dermatol; 2017 Jun; 44(6):e144-e145. PubMed ID: 28295551
[No Abstract] [Full Text] [Related]
37. Combination therapy of ipilimumab and nivolumab induced thyroid storm in a patient with Hashimoto's disease and diabetes mellitus: a case report.
Yonezaki K; Kobayashi T; Imachi H; Yoshimoto T; Kikuchi F; Fukunaga K; Sato S; Ibata T; Yamaji N; Lyu J; Dong T; Murao K
J Med Case Rep; 2018 Jun; 12(1):171. PubMed ID: 29914537
[TBL] [Abstract][Full Text] [Related]
38. Fundus Hypopigmentation and Loss of Choroidal Nevi Pigmentation Associated With Nivolumab.
Sophie R; Moses GM; Hwang ES; Kim JE
JAMA Ophthalmol; 2019 Jul; 137(7):851-853. PubMed ID: 31070667
[No Abstract] [Full Text] [Related]
39. Nivolumab therapy before vemurafenib administration induces a severe skin rash.
Imafuku K; Yoshino K; Ymaguchi K; Tsuboi S; Ohara K; Hata H
J Eur Acad Dermatol Venereol; 2017 Mar; 31(3):e169-e171. PubMed ID: 27546003
[No Abstract] [Full Text] [Related]
40. Complete ophthalmoplegia in Ipilmumab and Nivolumab combination treatment for metastatic melanoma.
Alnabulsi R; Hussain A; DeAngelis D
Orbit; 2018 Oct; 37(5):381-384. PubMed ID: 29381409
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]